Biomira's stock doubles as a result of drug test

The shares of Biomira increased 110% on Friday after positive test results for a new lung cancer vaccine, which was developed by Germany-based Merck and the Canadian biotech company. The promising results were found from the companies' BLP25 Liposome vaccine for the treatment of non-small cell lung cancer.

View Full Article in:

Globe and Mail (Toronto) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC